Proteasome inhibitors in glioblastoma (Review) Retraction in /10.3892/ol.2017.6921

Huang,Wen-Juan; Chen,Wei-Wei; Zhang,Xia

doi:10.3892/ol.2017.5585

Proteasome inhibitors in glioblastoma (Review)

Retraction in: /10.3892/ol.2017.6921

Authors:
- Wen-Juan Huang
- Wei-Wei Chen
- Xia Zhang
View Affiliations

Affiliations: Department of Neurology, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China, The Affiliated XuZhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu 221009, P.R. China, Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, Jiangsu 221009, P.R. China
Published online on: January 11, 2017 https://doi.org/10.3892/ol.2017.5585
Pages: 1058-1062
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastomas (GBM) are the tumors originating from the star shaped supportive cells in brain known as astrocytes. These tumors are highly cancerous as they have the ability to proliferate very quickly. New therapeutic strategies are being developed worldwide to fight against deadly GBM, which has median survival time of just 14 months. Proteasome inhibition is an upcoming strategy for GBM. Proteasome inhibition has shown promising results in cancers such as myeloma. However, in the recent past this form of therapy has also shown positive results in brain tumors in the form of elevated apoptosis. We searched the electronic database PubMed for pre-clinical as well as clinical controlled trials reporting importance of proteasome inhibitors during GBM. It was observed clearly that this approach is evolving and has been observed to be promising therapeutic avenue against GBM. Thus, the present review aims to enlighten the present views on use of proteasome inhibition strategy in the case of GBM.

View Figures

View References

1	Gilbert AN, Shevin RS, Anderson JC, Langford CP, Eustace N, Gillespie GY, Singh R and Willey CD: Generation of microtumors using 3D human biogel culture system and patient-derived glioblastoma cells for kinomic profiling and drug response testing. J Vis Exp. Jun 9–2016.(Epub ahead of print). doi: 10.3791/54026. View Article : Google Scholar
2	Hess KR, Broglio KR and Bondy ML: Adult glioma incidence trends in the United States, 1977–2000. Cancer. 101:2293–2299. 2004. View Article : Google Scholar : PubMed/NCBI
3	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
4	Johnson DR and O'Neill BP: Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 107:359–364. 2012. View Article : Google Scholar : PubMed/NCBI
5	Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al: Cancer Genome Atlas Research Network: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
6	Madhavan S, Zenklusen JC, Kotliarov Y, Sahni H, Fine HA and Buetow K: Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res. 7:157–167. 2009. View Article : Google Scholar : PubMed/NCBI
7	Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA, et al: Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 20:810–817. 2011. View Article : Google Scholar : PubMed/NCBI
8	Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, Ozawa T, Holland EC, Huse JT, Jhanwar S, et al: Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA. 109:3041–3046. 2012. View Article : Google Scholar : PubMed/NCBI
9	Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, et al: Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 344:1396–1401. 2014. View Article : Google Scholar : PubMed/NCBI
10	Kisselev AF and Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 8:739–758. 2001. View Article : Google Scholar : PubMed/NCBI
11	Groll M, Berkers CR, Ploegh HL and Ovaa H: Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 14:451–456. 2006. View Article : Google Scholar : PubMed/NCBI
12	Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H and Galardy PJ: Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods. 2:357–362. 2005. View Article : Google Scholar : PubMed/NCBI
13	Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J and Baldwin AS Jr: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61:3535–3540. 2001.PubMed/NCBI
14	Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J and McConkey DJ: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 1:1243–1253. 2002.PubMed/NCBI
15	Nawrocki ST, Sweeney-Gotsch B, Takamori R and McConkey DJ: The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 3:59–70. 2004.PubMed/NCBI
16	Ling YH, Liebes L, Zou Y and Perez-Soler R: Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem. 278:33714–33723. 2003. View Article : Google Scholar : PubMed/NCBI
17	Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:3071–3076. 2001.PubMed/NCBI
18	Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, et al: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 127:165–172. 2004. View Article : Google Scholar : PubMed/NCBI
19	Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 110:3557–3560. 2007. View Article : Google Scholar : PubMed/NCBI
20	Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, et al: Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 11:254–284. 2011. View Article : Google Scholar : PubMed/NCBI
21	Williams PG, Buchanan GO, Feling RH, Kauffman CA, Jensen PR and Fenical W: New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica. J Org Chem. 70:6196–6203. 2005. View Article : Google Scholar : PubMed/NCBI
22	Groll M, Huber R and Potts BCM: Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc. 128:5136–5141. 2006. View Article : Google Scholar : PubMed/NCBI
23	Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, et al: A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 8:407–419. 2005. View Article : Google Scholar : PubMed/NCBI
24	Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M and Orlowski RZ: Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 113:4667–4676. 2009. View Article : Google Scholar : PubMed/NCBI
25	Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, et al: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 15:781–787. 2009. View Article : Google Scholar : PubMed/NCBI
26	Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M and Chandra J: NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood. 110:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
27	Boatright KM and Salvesen GS: Mechanisms of caspase activation. Curr Opin Cell Biol. 15:725–731. 2003. View Article : Google Scholar : PubMed/NCBI
28	Styczynski J, Olszewska-Slonina D, Kolodziej B, Napieraj M and Wysocki M: Activity of bortezomib in glioblastoma. Anticancer Res. 26:4499–4503. 2006.PubMed/NCBI
29	Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL and Koeffler HP: Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene. 24:344–354. 2005. View Article : Google Scholar : PubMed/NCBI
30	Vlashi E, Mattes M, Lagadec C, Donna LD, Phillips TM, Nikolay P, McBride WH and Pajonk F: Differential effects of the proteasome inhibitor NPI-0052 against glioma cells. Transl Oncol. 3:50–55. 2010. View Article : Google Scholar : PubMed/NCBI
31	Pei XY, Dai Y and Grant S: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 10:3839–3852. 2004. View Article : Google Scholar : PubMed/NCBI
32	Pérez-Galán P, Roué G, Villamor N, Montserrat E, Campo E and Colomer D: The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 107:257–264. 2006. View Article : Google Scholar : PubMed/NCBI
33	Zou W, Yue P, Lin N, He M, Zhou Z, Lonial S, Khuri FR, Wang B and Sun SY: Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res. 12:273–280. 2006. View Article : Google Scholar : PubMed/NCBI
34	Baehrecke EH: Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol. 6:505–510. 2005. View Article : Google Scholar : PubMed/NCBI
35	Zhu K, Dunner K Jr and McConkey DJ: Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene. 29:451–462. 2010. View Article : Google Scholar : PubMed/NCBI
36	Selimovic D, Porzig BBOW, El-Khattouti A, Badura HE, Ahmad M, Ghanjati F, Santourlidis S, Haikel Y and Hassan M: Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells. Cell Signal. 25:308–318. 2013. View Article : Google Scholar : PubMed/NCBI
37	Yao F, Wang G, Wei W, Tu Y, Tong H and Sun S: An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells. Mol Med Rep. 5:84–88. 2012.PubMed/NCBI
38	Ding WX, Ni HM, Gao W, Chen X, Kang JH, Stolz DB, Liu J and Yin XM: Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther. 8:2036–2045. 2009. View Article : Google Scholar : PubMed/NCBI
39	Belloni D, Veschini L, Foglieni C, Dell'Antonio G, Caligaris-Cappio F, Ferrarini M and Ferrero E: Bortezomib induces autophagic death in proliferating human endothelial cells. Exp Cell Res. 316:1010–1018. 2010. View Article : Google Scholar : PubMed/NCBI
40	Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR and Begley DJ: Structure and function of the blood-brain barrier. Neurobiol Dis. 37:13–25. 2010. View Article : Google Scholar : PubMed/NCBI
41	Zünkeler B, Carson RE, Olson J, Blasberg RG, DeVroom H, Lutz RJ, Saris SC, Wright DC, Kammerer W, Patronas NJ, et al: Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg. 85:1056–1065. 1996. View Article : Google Scholar : PubMed/NCBI
42	Balyasnikova IV, Ferguson SD, Han Y, Liu F and Lesniak MS: Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Lett. 310:148–159. 2011. View Article : Google Scholar : PubMed/NCBI
43	Asklund T, Kvarnbrink S, Holmlund C, Wibom C, Bergenheim T, Henriksson R and Hedman H: Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. Anticancer Res. 32:2407–2413. 2012.PubMed/NCBI
44	Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon E, et al: Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol. 14:215–221. 2012. View Article : Google Scholar : PubMed/NCBI
45	Singh AV, Palladino MA, Lloyd GK, Potts BC, Chauhan D and Anderson KC: Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol. 149:550–559. 2010. View Article : Google Scholar : PubMed/NCBI
46	Berkowitz A and Walker S: Bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Clin J Oncol Nurs. 16:86–89. 2012. View Article : Google Scholar : PubMed/NCBI
47	Argyriou AA, Iconomou G and Kalofonos HP: Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 112:1593–1599. 2008. View Article : Google Scholar : PubMed/NCBI
48	Wolf S, Barton D, Kottschade L, Grothey A and Loprinzi C: Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 44:1507–1515. 2008. View Article : Google Scholar : PubMed/NCBI
49	Richardson PG, Spencer A, Cannell P, Harrison SJ, Catley L, Underhill C, Zimmerman TM, Hofmeister CC, Jakubowiak AJ, Laubach J, et al: Phase I clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). Blood (ASH Annual Meeting abst). 118:3022011.
50	Fuchs D, Berges C, Opelz G, Daniel V and Naujokat C: Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem. 103:270–283. 2008. View Article : Google Scholar : PubMed/NCBI
51	Chauhan D, Hideshima T and Anderson KC: A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer. 95:961–965. 2006. View Article : Google Scholar : PubMed/NCBI
52	Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, et al: Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res. 17:5101–5112. 2011. View Article : Google Scholar : PubMed/NCBI
53	Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene expression and chemoresistance of CD133⁺ cancer stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
54	Lucio-Eterovic AK, Cortez MA, Valera ET, Motta FJ, Queiroz RG, Machado HR, Carlotti CG Jr, Neder L, Scrideli CA and Tone LG: Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer. 8:2432008. View Article : Google Scholar : PubMed/NCBI
55	Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA and Marks PA: Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA. 93:5705–5708. 1996. View Article : Google Scholar : PubMed/NCBI
56	Marks PA and Breslow R: Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 25:84–90. 2007. View Article : Google Scholar : PubMed/NCBI
57	Mann BS, Johnson JR, Cohen MH, Justice R and Pazdur R: FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 12:1247–1252. 2007. View Article : Google Scholar : PubMed/NCBI
58	Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T and Nakanishi O: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA. 96:4592–4597. 1999. View Article : Google Scholar : PubMed/NCBI
59	Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Hammond S, Grimm SA, Norden AD, Beroukhim R, McCluskey CS, et al: Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma. J Clin Oncol. 31:ASCO abst. 2013.